Efficacy of Systemic Bevacizumab for Recurrent Respiratory Papillomatosis with Pulmonary Involvement
The Laryngoscope · 2024
DOI: 10.1002/lary.30893 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Laryngoscope, 2024. Verfasst von Raymond J So und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, U.S.A. Hauptthemen laut MEDLINE: Respiratory Tract Infections, Papillomavirus Infections, Lung Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
Objectives
Pulmonary papillomatosis is a rare but severe manifestation of recurrent respiratory papillomatosis (RRP). Efficacy data of systemic bevacizumab for pulmonary RRP are limited. This study's objective was to characterize disease response of pulmonary RRP to systemic bevacizumab.
Methods
A retrospective review was performed to identify patients with pulmonary RRP seen at three medical institutions. Clinical symptoms, CT findings, and disease response were compared before and after initiation of systemic bevacizumab therapy. Disease response was categorized as complete response, partial response, stabilization, or progression for each subsite involved by papilloma.
Results
Of the 12 pulmonary RRP patients treated with systemic bevacizumab, 4 (33.3%) were male, and 11 (91.7%) were juvenile‐onset RRP patients. All presented with laryngeal, tracheal, and pulmonary RRP. The median (range) age at first bevacizumab infusion was 48.1 (19.5–70.2) years. Progression to pulmonary malignancy was identified in 3 (25.0%) patients, 2 before initiation of and 1 after complete cessation of bevacizumab therapy. Clinical symptoms such as dyspnea (75.0% vs. 25.0%; p = 0.01) and dysphagia and/or odynophagia (33.3 vs. 0.0%; p = 0.03) were significantly decreased following bevacizumab therapy. Compared with pre‐treatment baseline, 9 (75.0%) patients experienced a stable‐to‐partial response in the lungs to systemic bevacizumab, and 10 (83.3%) experienced partial‐to‐complete responses in the larynx and trachea.
Conclusion
Systemic bevacizumab is effective in stabilizing progression in even the most severe cases of RRP, with both a dramatic reduction in laryngeal and tracheal disease as well as a stable‐to‐partial response of pulmonary involvement in a majority of patients. Level of Evidence 4 Laryngoscope , 134:577–581, 2024
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, U.S.A.
- Department of Otolaryngology-Head and Neck Surgery, Emory University, Atlanta, Georgia, U.S.A.
- Department of Hematology and Medical Oncology, Emory University, Atlanta, Georgia, U.S.A.
- Department of Pharmaceutical Sciences, Emory University, Atlanta, Georgia, U.S.A.
- Highlands Oncology, Fayetteville, Arkansas, U.S.A.
- Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, U.S.A.
ORCID-Profile: Raymond J So
Zitieren
APA
So, R. J., Hidalgo Lopez, J. C., Ballestas, S. A., Klein, A. M., Steuer, C., Shin, D. M., Abousaud, M., Teng, Y., Saba, N. F., Tkaczuk, A. T., Schaefer, E. S., Seiwert, T. Y., McClellan, K., & Best, S. R. (2024). Efficacy of Systemic Bevacizumab for Recurrent Respiratory Papillomatosis with Pulmonary Involvement. The Laryngoscope. https://doi.org/10.1002/lary.30893
Vancouver
So RJ, Hidalgo Lopez JC, Ballestas SA, Klein AM, Steuer C, Shin DM, et al. Efficacy of Systemic Bevacizumab for Recurrent Respiratory Papillomatosis with Pulmonary Involvement. The Laryngoscope. 2024. doi:10.1002/lary.30893
BibTeX
@article{So2024,
author = {So, Raymond J and Hidalgo Lopez, Julio C and Ballestas, Samir A and Klein, Adam M and Steuer, Conor and Shin, Dong M and Abousaud, Marin and Teng, Yong and Saba, Nabil F and Tkaczuk, Andrew T and Schaefer, Eric S and Seiwert, Tanguy Y and McClellan, Kim and Best, Simon R},
title = {Efficacy of Systemic Bevacizumab for Recurrent Respiratory Papillomatosis with Pulmonary Involvement},
journal = {The Laryngoscope},
year = {2024},
doi = {10.1002/lary.30893}
}
EUVIMED